-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Summit Therapeutics, Lowers Price Target to $42

Benzinga·11/16/2026 18:55:04
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $43 to $42.